All In Biotech

Drug Trial Radar · NCT06892431

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

A Phase II Clinical Study of JMT101 Injection Combined With Mitoxantrone Liposome Injection in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Cancer Who Have Failed At Least Two Prior Lines of Treatment

Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Dec 31, 2025

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with recurrent/metastatic nasopharyngeal cancer who have failed at least two prior lines of treatment.

Conditions

  • Recurrent or Metastatic Nasopharyngeal Cancer
  • Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy

Interventions

  • Mitoxantrone Hydrochloride LiposomeDrug

    Mitoxantrone Hydrochloride Liposome Injection 20mg/m2, or 16mg/m2, intravenous drip, Q4W.

  • JMT101 injectionDrug

    JMT101 Injection 6 mg/kg, intravenous drip,

  • CapecitabineDrug

    The dosage of capecitabine is 1000 mg/m2, taken orally twice daily, administered on D1-14 (Days 1-14) of each cycle, with every 3 weeks as one cycle (Q3W);

  • Docetaxel injectionDrug

    The dosage of docetaxel is 75 mg/m2, administered via intravenous drip on D1 of each cycle, Q3W.

  • Gemcitabine hydrochloride for injectionDrug

    The dosage of gemcitabine is 1000 mg/m2, administered via intravenous drip on D1 and D8 (Day 1 and Day 8) of each cycle, Q3W;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) per RECIST v1.1Time frame: Up to approximately 30 months after the first participant is enrolled

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.